Trial Profile

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 9574 (Primary) ; Radiopharmaceuticals (Primary) ; Temozolomide (Primary)
Indications Advanced breast cancer; Brain metastases; Carcinoma; Fallopian tube cancer; Glioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer
Focus Adverse reactions; First in man
Acronyms CERTIS1
Sponsors AstraZeneca

28 May 2025 Planned number of patients changed from 270 to 535.
26 Mar 2025 Planned End Date changed from 28 Aug 2026 to 19 Feb 2027.
26 Mar 2025 Planned primary completion date changed from 28 Aug 2026 to 19 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com